Clinithink

Clinithink operates as a specialized health-tech firm, focusing on transforming unstructured clinical data into structured, actionable information for the healthcare and life sciences sectors. The company was founded in 2009 by Dr. Chris Tackaberry and Peter Johnson, both of whom are former practicing physicians. Dr. Tackaberry's background combines nine years in clinical practice, specifically in anesthesiology and intensive care, with a Master's degree in computer science, a fusion of expertise that shaped the company's direction. The founders' experience with the limitations of structured data and the richness of narrative clinical notes directly inspired the company's core mission.

The company's core offering is the CLiX (Clinical Language Indexing) intelligence platform, which utilizes patented Clinical Natural Language Processing (CNLP) technology. This AI-powered platform is engineered to interpret the complex and nuanced language, including shorthand and metaphors, found in clinicians' daily notes. The CLiX platform can analyze millions of clinical documents in hours, a task that would otherwise require immense manual effort from clinicians. Its capabilities include identifying intricate clinical concepts by comparing text to the structured vocabulary of SNOMED CT. The technology is designed to handle misspellings, acronyms, and various ways of expressing a single medical fact.

Clinithink's business model is centered on providing its solutions to a diverse client base that includes pharmaceutical companies, healthcare providers, and government organizations. Its clients, such as AstraZeneca and Mount Sinai, use the technology for a variety of purposes including disease management, optimizing healthcare reimbursement, and accelerating drug development. For life sciences clients, the platform aids in generating real-world evidence and identifying eligible candidates for clinical trials by mining the narrative text in medical records. For healthcare providers, it helps improve population health outcomes by identifying risks, detecting rare diseases, and tracking disease progression. Since its inception, Clinithink has secured significant funding, including a multi-million dollar Series A round in 2012 and subsequent investments from entities like the Development Bank of Wales, TT Capital Partners, and the MSD Global Health Innovation Fund to fuel its growth and US expansion.

Keywords: Clinical Natural Language Processing, unstructured clinical data, healthcare data analytics, life sciences technology, CLiX intelligence platform, real-world evidence, clinical trial recruitment, population health management, revenue cycle management, medical data interpretation, SNOMED CT, physician notes analysis, Chris Tackaberry, Peter Johnson, health-tech, clinical decision support, rare disease detection, patient cohort analysis, care quality improvement, healthcare AI